KR920017653A - 플루나리진을 함유하는 항종양제 조성물 - Google Patents

플루나리진을 함유하는 항종양제 조성물 Download PDF

Info

Publication number
KR920017653A
KR920017653A KR1019920003713A KR920003713A KR920017653A KR 920017653 A KR920017653 A KR 920017653A KR 1019920003713 A KR1019920003713 A KR 1019920003713A KR 920003713 A KR920003713 A KR 920003713A KR 920017653 A KR920017653 A KR 920017653A
Authority
KR
South Korea
Prior art keywords
flunarizine
tumor
effective amount
tumor agent
agent
Prior art date
Application number
KR1019920003713A
Other languages
English (en)
Inventor
프란시스쿠스 반 진크켈 로베르트
빅토르 마리아 반헤르크 빔
Original Assignee
디르크 반테
잔센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디르크 반테, 잔센 파마슈티카 엔.브이. filed Critical 디르크 반테
Publication of KR920017653A publication Critical patent/KR920017653A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

플루나리진을 함유하는 항종양제 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 약제학적으로 허용되는 담체, 및 활성성분으로서 유효량의 플루나리진과 항종양제를 함유하는 약제 조성물.
  2. 제1항에 있어서, 항종양제가 빈크리스틴 (vincristine), 빈블라스틴 (vinblastime), 악티노마이신 (actinomycin) D 또는 F1, 그리미시딘 (gramiciding), 콜치신 (colchicine), 에토포사이드 (etoposide), 테니포사이드 (tenioside), 또는 아드리아마이신(adriamycin)인 조성물.
  3. 제1 또는 2항에 있어서, 사이클로덱스트린 또는 그의 유도체를 추가로 함유하는 조성물.
  4. 유효량의 플루나리진과 항종양제를 약제학적으로 허용되는 담체와 완전히 혼합함을 특징으로 하여 제 1내지 3항중 어느 하나에서 청구한 약제 조성물을 제조하는 방법.
  5. 유효량의 플루나리진과 항종양제를 투여함을 특징으로 하여, 종양성 질환으로 고생하는 환자의 질환을 치료 하거나 종양의 성장이 발생할것 같은 환자에게 있어 종양의 성장을 회피하는 방법.
  6. 종양성 질환으로 고생하거나 종양성 질환이 발병할것 같은 환자에게 유효량의 플루나리진을 투여함을 특징으로 하여, 상기 환자에게 있어서 항종양제 치료요법에 대해 발달 또는 존재하는 내성을 감소 또는 소멸시키는 방법.
  7. 항종양 치료요법에 병용, 분리 또는 연속사용하기 위한 제제로서 플루나리진과 항종양제를 함유하는 제품.
  8. 제7항에 있어서, 플루나리진을 함유하는 적합한 조성물이 담긴 용기 및 항종양제를 함유하는 조성물이 담긴 또다른 용기를 포함하는 키트(kit)로 이루어진 제품.
  9. 종양성 질환으로 고생하는 환자의 질환 치료용 또는 종양의 성장이 발생할 것 같은 환자에게 있어 종양의 성장 회피용 약제를 제조하기 위한 플루나진의 용도.
  10. 종양성 질환으로 고생하는 환자에게 있어 항종양제 치료요법에 대해 발달 또는 존재하는 내성의 감소 또는 소멸용, 또는 이러한 내성의 발달 회피용 약제를 제조하기 위한 플루나진의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019920003713A 1991-03-08 1992-03-06 플루나리진을 함유하는 항종양제 조성물 KR920017653A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP91200502 1991-03-08
EP91200502.2 1991-03-08

Publications (1)

Publication Number Publication Date
KR920017653A true KR920017653A (ko) 1992-10-21

Family

ID=8207537

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920003713A KR920017653A (ko) 1991-03-08 1992-03-06 플루나리진을 함유하는 항종양제 조성물

Country Status (9)

Country Link
EP (1) EP0503710A3 (ko)
JP (1) JPH0597675A (ko)
KR (1) KR920017653A (ko)
AU (1) AU650513B2 (ko)
CA (1) CA2061891A1 (ko)
IE (1) IE920733A1 (ko)
IL (1) IL101163A (ko)
NO (1) NO300305B1 (ko)
ZA (1) ZA921713B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9650398A (en) * 1997-11-07 1999-05-31 Daiichi Pharmaceutical Co., Ltd. Piperazine-cyclodextrin complexes
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US20110200686A1 (en) * 2008-04-07 2011-08-18 University Og Washington Compositions of modulators of the wnt/b-catenin pathway and an n-cinnamyl-n'benzhydryl piperazine and their use in treating neoplastic conditions including malignant melanoma
JP7267640B2 (ja) * 2018-10-17 2023-05-02 江▲蘇▼▲領▼航生物科技有限公司 希釈安定性に優れたテニポシド注射用溶液及びその調製方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin

Also Published As

Publication number Publication date
IL101163A (en) 1997-06-10
ZA921713B (en) 1993-09-06
EP0503710A3 (en) 1993-07-28
NO920903L (no) 1992-09-09
NO300305B1 (no) 1997-05-12
CA2061891A1 (en) 1992-09-09
AU1144792A (en) 1992-09-10
IE920733A1 (en) 1992-09-09
EP0503710A2 (en) 1992-09-16
AU650513B2 (en) 1994-06-23
IL101163A0 (en) 1992-11-15
JPH0597675A (ja) 1993-04-20
NO920903D0 (no) 1992-03-06

Similar Documents

Publication Publication Date Title
ATE152910T1 (de) Verwendung von taxol zur herstellung eines arzneimittels zur behandlung von krebs
YU48583B (sh) Postupak za pripremanje formulacije u obliku pilule za oralno davanje
TW366286B (en) Flavour-masked pharmaceutical compositions
GEP20032925B (en) Benzothiepines Having Activity As Inhibitors of Ileal Bile Acid Transport and Taurocholate Uptake
DE3070189D1 (en) Medicament, particularly for the treatment of cholera, and pharmaceutical compositions containing it
IL103303A (en) Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
DE69320646D1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
KR940018089A (ko) 내부조직의 방사선 손상에 대한 예방 및 처치방법
ES2088959T3 (es) 11-beta-aril-4-estreno, procedimiento para su preparacion y aplicacion como medicamento.
KR930005619A (ko) 위장 질환 치료용 약제
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
ATE74006T1 (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
AU1206292A (en) Therapeutic agents for the treatment of multidrug resistance to cancers
KR970061244A (ko) 치매 치료용 약학 조성물
KR920017653A (ko) 플루나리진을 함유하는 항종양제 조성물
FR2500303B1 (ko)
DE60035133D1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
KR920702225A (ko) 약학 조성물
GEP20022613B (en) Compositions with Beneficial Organoleptic Properties and Their Solvates, Method for Their Production and Pharmaceutical Compound Containing the Same
DE3163920D1 (en) Pharmaceutical preparations comprising polyprenyl compounds, especially as anti-cancer agents, and pharmaceutical compositions for the prevention and treatment of cancer and skin diseases
KR900017599A (ko) 종양 치료용 약학 조성물
Miki et al. Antitumor effect of recombinant human tumor necrosis factor on human testicular tumors heterotransplanted in nude mice
KR910002455A (ko) 아크릴산 유도체를 함유하는 제약 조성물 및 의약으로서 이들의 사용
JPH09188624A (ja) 肝性脳症治療剤又は肝性脳症予防剤

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application